ArticleInternational orthopaedics2018
Association of reduced sclerostin expression with collapse process in patients with osteonecrosis of the femoral head.
Article in International orthopaedics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Decreased serum 4-Hydroxynonenal level as a biomarker for the progression of steroid-induced osteonecrosis of the femoral head.Journal of orthopaedic surgery and research · 2023Article
- Mechanical properties of trabeculae and osteocyte morphology change significantly in different areas of the necrotic femoral head.Frontiers in cell and developmental biology · 2023Article
- Serum β-catenin changes vary among different stages of osteonecrosis of the femoral head: an exploratory biomarker study.BMC musculoskeletal disorders · 2022Article
- Plasma lipidomics analysis reveals altered lipids signature in patients with osteonecrosis of the femoral head.Metabolomics : Official journal of the Metabolomic Society · 2022Article
- The Role of Sclerostin in Bone Diseases.Journal of clinical medicine · 2022Review
- [Clinical significance of different imaging manifestations of osteonecrosis of femoral head in the peri-collapse stage].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2021Article
- Exploring the Risk Factors for the Misdiagnosis of Osteonecrosis of Femoral Head: A Case-Control Study.Orthopaedic surgery · 2020Article
- Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update.The Journal of bone and joint surgery. American volume · 2020Review
- Rapid Discovery of Potential Drugs for Osteonecrosis of Femoral Head Based on Gene Expression Omnibus Database and Connectivity Map.Orthopaedic surgery · 2019Article
- Hip osteonecrosis: stem cells for life or behead and arthroplasty?International orthopaedics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSclerostin is an osteocyte-derived protein that has a potent inhibitory effect on osteoblast activity. The osteocyte apoptosis induced by various causes of osteonecrosis of the femoral head (ONFH) plays a key role in the promotion of femoral head collapse. But the effect of altering sclerostin level on the collapse of ONFH has not been studied. Our aim was to assess the role of sclerostin level in the collapse of ONFH.
methodsBetween May 2016 and November 2016, 236 subjects were enrolled in the present study. The patients were classified according to the Association Research Circulation Osseous (ARCO) classification. The clinical bone histomorphology, the expression position, and level of sclerostin as well as the plasma sclerostin level were evaluated.
resultsThe sclerostin level was significantly lower in the non-traumatic ONFH group than those in the healthy control group (P = 0.002). The sclerostin level was negatively associated with ARCO stages (r = - 0.239, P = 0.009) and significantly lower in the postcollapse group (P = 0.025).
conclusionsThe reduced expression of sclerostin may play a key role in the collapse process of ONFH and be predictive of the disease progression of ONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.